• Explore /
  • Poster
  • / A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).

A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).

Abstract Poster

Authors

null

Helene Senellart

Institut de Cancerologie de l'Ouest, Nantes, France

Helene Senellart , Emmanuelle Samalin , Florence Castan , Christophe Borg , Antoine Adenis , Christelle De La Fouchardiere , David Malka , Veronique Guerin-Meyer , Eric Francois , Meher Ben Abdelghani , Eveline Boucher , Thierry Andre , Francois Ghiringhelli , Astrid Lievre , Trevor Stanbury , Jaafar Bennouna

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01919879

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3537)

DOI

10.1200/JCO.2016.34.15_suppl.3537

Abstract #

3537

Poster Bd #

234

Abstract Disclosures

Similar Posters

First Author: Hélène Senellart

First Author: Yuki Matsubara

First Author: Robert William Lentz

First Author: Daisuke Kotani